8-K: Brainstorm Cell Therapeutics Announces Q3 2024 Financial Results and Provides Update on NurOwn Program

Brainstorm Cell Therapeutics reported its third quarter 2024 financial results and provided an update on the progress of its NurOwn program for ALS, including a planned Phase 3b trial.

Summary

• Brainstorm Cell Therapeutics announced its financial results for the third quarter ended September 30, 2024, and provided a corporate update focusing on the NurOwn program.
• The company is preparing for a Phase 3b registration trial of NurOwn in ALS, having refined the trial design based on previous study learnings.
• A Memorandum of Understanding (MOU) was signed with Pluri Inc. to manufacture NurOwn for the Phase 3b trial, enabling immediate technology transfer and production.
• The Phase 3b trial is expected to enroll approximately 200 participants with ALS, with a two-part design involving 24 weeks of treatment with either NurOwn or placebo, followed by an open-label period where all patients receive NurOwn.
• The primary efficacy endpoint of the trial is the change in ALSFRS-R from baseline to week 24.
• Brainstorm presented data from an Expanded Access Program (EAP) showing promising long-term survival benefits for NurOwn-treated patients compared to matched controls, with a median survival time of 46.6 months versus 41.1 months.
• The company's cash, cash equivalents, and restricted cash amounted to approximately $0.35 million as of September 30, 2024.
• Research and development expenses were $1 million for the third quarter of 2024, compared to $3.3 million for the same period in 2023.
• The net loss for the third quarter of 2024 was $2.7 million, compared to a net loss of $1.2 million for the third quarter of 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in the clinical development of NurOwn and promising EAP data, the company's financial situation is concerning with a low cash balance and increased net loss. This creates uncertainty about the company's ability to continue operations and fund the Phase 3b trial.

Positives

• The company is actively moving forward with the Phase 3b trial for NurOwn in ALS.
• The partnership with Pluri Inc. secures manufacturing capabilities for the trial.
• The refined trial design is expected to increase the probability of demonstrating a treatment effect.
• The EAP data showed a statistically significant survival benefit for NurOwn treated patients.
• Consistent reductions in neurofilament light (NfL) were observed, indicating a positive impact on neurodegeneration.

Negatives

• The company's cash position is very low at approximately $0.35 million.
• The net loss increased to $2.7 million in Q3 2024 compared to $1.2 million in Q3 2023.
• Research and development expenses decreased significantly from $3.3 million to $1 million, which may indicate a slowdown in research activities.

Risks

• The company's low cash position raises concerns about its ability to fund ongoing operations and the Phase 3b trial.
• The success of the Phase 3b trial is not guaranteed, and failure could significantly impact the company's future.
• The company is reliant on the successful finalization of the definitive agreement with Pluri Inc.
• There are inherent risks and uncertainties associated with clinical trials and regulatory approvals.
• The company's ability to continue as a going concern is dependent on raising additional capital.

Future Outlook

The company is focused on preparing for the Phase 3b trial of NurOwn in ALS and is working with Pluri Inc. for manufacturing. They plan to host a conference call in Q4 2024 to provide further updates.

Management Comments

• BrainStorm's primary focus continues to be preparing for the upcoming Phase 3b registration trial of NurOwn in ALS, said Chaim Lebovits, President and CEO of Brainstorm.
• We have carefully refined the trial design based on the learnings from our previous study, and we believe this will increase the probability of demonstrating a treatment effect.
• We remain committed to the ALS community as we work to advance NurOwn and deliver a therapeutic option that we believe will make a difference for patients and their families.

Industry Context

The announcement is relevant to the broader field of neurodegenerative disease therapeutics, particularly in the development of cell-based therapies for ALS. The partnership with Pluri Inc. highlights the importance of manufacturing capabilities in this sector. The focus on a Phase 3b trial reflects the ongoing efforts to bring new treatments to market for ALS, a disease with limited therapeutic options.

Comparison to Industry Standards

• The Phase 3b trial design, with a focus on early-stage ALS patients and a primary endpoint of ALSFRS-R change, is consistent with industry standards for ALS clinical trials.
• The use of neurofilament light (NfL) as a biomarker is also in line with current research trends in neurodegenerative diseases.
• The reported median survival time of 46.6 months in the EAP is a positive signal, but it is important to compare this to other ALS studies and treatments to fully assess its significance.
• Companies like Biogen and Amylyx Pharmaceuticals have also been developing treatments for ALS, and the results of Brainstorm's Phase 3b trial will be closely watched in comparison to these other therapies.

Stakeholder Impact

• Shareholders may be concerned about the company's low cash position and increased net loss.
• Patients with ALS and their families may be encouraged by the progress of the NurOwn program and the potential for a new treatment option.
• Employees may be impacted by the company's financial situation and potential need for cost-cutting measures.
• The partnership with Pluri Inc. may have a positive impact on suppliers and other stakeholders.

Next Steps

• Finalizing the definitive agreement with Pluri Inc. for NurOwn manufacturing.
• Initiating the Phase 3b clinical trial for NurOwn in ALS.
• Hosting a conference call and webcast in Q4 2024 to provide further updates on the NurOwn program.

Key Dates

Keywords

NurOwn, ALS, Phase 3b trial, stem cell therapy, neurodegenerative diseases, clinical trial, biomarker, manufacturing, financial results, EAP, survival, neurofilament light